- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHARMASIMPLE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 3,910 | -1,76 % | Innocan Pharma Corporation: Innocan Pharma Announces Closing of Additional Debenture | The Debenture will bear interest at the rate of 10% per annum and matures at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed... ► Artikel lesen | |
| SYNBIOTIC | 2,000 | -1,23 % | EQS-News: SYNBIOTIC SE: SYNBIOTIC startet mit operativem Fortschritt, neuen regulatorischen Impulsen und starker Branchenpräsenz ins Frühjahr 2026 | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Marktbericht/Prognose
SYNBIOTIC startet mit operativem Fortschritt, neuen regulatorischen Impulsen und starker Branchenpräsenz ins Frühjahr... ► Artikel lesen | |
| BIONANO GENOMICS | 1,160 | -1,28 % | Bionano Genomics: Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026 | SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 152,50 | +3,01 % | Axsome Therapeutics, Inc.: Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 | ||
| JAGUAR HEALTH | 0,374 | -5,89 % | Jaguar Health, Inc.: Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea in Dogs | Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyrosine... ► Artikel lesen | |
| TRULIEVE CANNABIS | 5,340 | +0,75 % | Trulieve Cannabis Corp.: Trulieve Reports Fourth Quarter and Full Year 2025 Results with 60% Gross Margin and Record Cash Flow Generation | Full year revenue of $1.2 billion, with 60% gross margin
Record 2025 cash flow from operations of $273 million and free cash flow of $229 million*
Record 50.1... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 224,80 | -1,36 % | West Pharmaceutical Services President And CEO Eric Green To Retire | WASHINGTON (dpa-AFX) - West Pharmaceutical Services, Inc. (WST) announced that Eric Green plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the... ► Artikel lesen | |
| KALA BIO | 0,160 | +4,23 % | KALA BIO, Inc.: Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities | TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation... ► Artikel lesen | |
| SHIONOGI | 18,480 | -6,22 % | Shionogi USA: ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja/Fetcroja (cefiderocol) in MBL-Producing Enterobacterales Infections | Real-world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta lactamase... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,251 | -16,74 % | Theriva Biologics, Inc. - 8-K, Current Report | ||
| CHARLOTTES WEB | 0,486 | -2,80 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports 2025 Fourth Quarter and Full Year Financial Results | Anticipated CMMI Medicare Pilot Program Participation, Regulatory Momentum, and Cost Structure Improvements Position Company for Growth and Pathway to Profitability
... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 1,900 | -2,16 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application | NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,460 | 0,00 % | Beximco Pharma: Gerichtsanhörung auf nach April verschoben | ||
| LUYE PHARMA | 0,304 | -4,40 % | LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S INNOVATIVE DRUG LY03020 | ||
| THERAPEUTICSMD | 1,690 | -1,74 % | XFRA NEW INSTRUMENTS AVAILABLE ON 10.12.2025 | The following instruments on XETRA do have their first trading 10.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.12.2025
Aktien
1 JP3108030002 Axyz Co. Ltd.
2 JP3431200009... ► Artikel lesen |
Das Unternehmen PHARMASIMPLE SA kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMASIMPLE SA finden Sie auf Wallstreet Online.